Product Code: ETC13331891 | Publication Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 150 | No. of Figures: 55 | No. of Tables: 32 |
Europe Large Molecules Drug Substance CDMO Market |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Europe Large Molecules Drug Substance CDMO Market Overview |
3.1 Europe Regional Macro Economic Indicators |
3.2 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume, 2021 & 2031F |
3.3 Europe Large Molecules Drug Substance CDMO Market - Industry Life Cycle |
3.4 Europe Large Molecules Drug Substance CDMO Market - Porter's Five Forces |
3.5 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Service Type, 2021 & 2031F |
3.7 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
3.8 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Stage, 2021 & 2031F |
3.9 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.10 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 Europe Large Molecules Drug Substance CDMO Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Europe Large Molecules Drug Substance CDMO Market Trends |
6 Europe Large Molecules Drug Substance CDMO Market, 2021 - 2031 |
6.1 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
6.1.1 Overview & Analysis |
6.1.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Process Development, 2021 - 2031 |
6.1.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Manufacturing, 2021 - 2031 |
6.1.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Analytical Services, 2021 - 2031 |
6.1.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Regulatory Support, 2020 - 2028 |
6.1.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Packaging, 2020 - 2028 |
6.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
6.2.1 Overview & Analysis |
6.2.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031 |
6.2.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Recombinant Proteins, 2021 - 2031 |
6.2.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Peptides, 2021 - 2031 |
6.2.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Nucleic Acids, 2021 - 2031 |
6.2.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Viral Vectors, 2020 - 2028 |
6.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
6.3.1 Overview & Analysis |
6.3.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Preclinical, 2021 - 2031 |
6.3.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Clinical, 2021 - 2031 |
6.3.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Commercial, 2021 - 2031 |
6.3.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Late-Stage, 2021 - 2031 |
6.3.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Early-Stage, 2021 - 2031 |
6.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
6.4.1 Overview & Analysis |
6.4.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Oncology, 2021 - 2031 |
6.4.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Immunology, 2021 - 2031 |
6.4.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Neurology, 2020 - 2028 |
6.4.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Rare Diseases, 2020 - 2028 |
6.4.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Infectious Diseases, 2020 - 2028 |
6.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2020 - 2028 |
6.5.1 Overview & Analysis |
6.5.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Pharmaceutical Companies, 2020 - 2028 |
6.5.3 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Biopharmaceutical Companies, 2020 - 2028 |
6.5.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Research Institutes, 2020 - 2028 |
6.5.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By CROs, 2020 - 2028 |
6.5.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By CMOs, 2020 - 2028 |
7 Europe Large Molecules Drug Substance CDMO Market, By Countries, 2021 - 2031 |
7.1 Overview & Analysis |
7.2 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.1 United Kingdom (UK) Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.2 Germany Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.3 France Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.4 Poland Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.5 Spain Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.2.6 Rest of Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Service Type, 2021 - 2031 |
7.3 Europe Large Molecules Drug Substance CDMO Market Revenues & Volume Share, By Molecule Type, 2021 & 2031F |
7.3.1 United Kingdom (UK) Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.3.2 Germany Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.3.3 France Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.3.4 Poland Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.3.5 Spain Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.3.6 Rest of Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Molecule Type, 2021 - 2031 |
7.4 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.1 United Kingdom (UK) Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.2 Germany Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.3 France Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.4 Poland Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.5 Spain Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.4.6 Rest of Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Stage, 2021 - 2031 |
7.5 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.1 United Kingdom (UK) Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.2 Germany Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.3 France Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.4 Poland Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.5 Spain Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.5.6 Rest of Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By Application, 2021 - 2031 |
7.6 Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.1 United Kingdom (UK) Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.2 Germany Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.3 France Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.4 Poland Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.5 Spain Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
7.6.6 Rest of Europe Large Molecules Drug Substance CDMO Market, Revenues & Volume, By End User, 2021 - 2031 |
8 Europe Large Molecules Drug Substance CDMO Market Key Performance Indicators |
9 Europe Large Molecules Drug Substance CDMO Market - Export/Import By Countries Assessment |
10 Europe Large Molecules Drug Substance CDMO Market - Opportunity Assessment |
10.1 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Countries, 2021 & 2031F |
10.2 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Service Type, 2021 & 2031F |
10.3 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Molecule Type, 2021 & 2031F |
10.4 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Stage, 2021 & 2031F |
10.5 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By Application, 2021 & 2031F |
10.6 Europe Large Molecules Drug Substance CDMO Market Opportunity Assessment, By End User, 2021 & 2031F |
11 Europe Large Molecules Drug Substance CDMO Market - Competitive Landscape |
11.1 Europe Large Molecules Drug Substance CDMO Market Revenue Share, By Companies, 2022 |
11.2 Europe Large Molecules Drug Substance CDMO Market Competitive Benchmarking, By Operating and Technical Parameters |
12 Top 10 Company Profiles |
13 Recommendations |
14 Disclaimer |